All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the latest updates on trispecific antibodies for the treatment of MM?
Featured
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What are the latest updates on trispecific antibodies for the treatment of multiple myeloma?
What are the latest updates on trispecific antibodies for the treatment of MM?
Mohty begins by sharing the latest results from the phase I trial of HPN217 (NCT04184050), a B-cell maturation antigen-targeted trispecific antibody, for the treatment of relapsed/refractory multiple myeloma. He then provides background on the structure and mechanism of action of HPN217 and outlines the latest safety and efficacy data from the dose escalation phase. Finally, Mohty offers his expert perspective on the ongoing development and clinical applications of trispecific antibodies in the treatment of multiple myeloma.
Your opinion matters
28 votes - 3 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox